eFFECTOR Therapeutics, Inc.: Nasdaq/NYSE listing notice — eFFECTOR receives Nasdaq notice for MVLS below $35M; 180-day cure period until Nov 12, 2024

eFFECTOR Therapeutics, Inc.

Notice dated May 16, 2024 for failure to meet $35M minimum value of listed securities for 30 consecutive business days.
Company has until November 12, 2024 to regain compliance by closing at $35M+ for 10 consecutive business days.
If non-compliant, Nasdaq may delist common stock (EFTR) and warrants (EFTRW).
Alternative compliance standard: maintain minimum stockholders' equity of $2.5M under Rule 5550(b)(1).
Management evaluating options but cannot assure regaining compliance or continued listing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

eFFECTOR Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

May 16, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the Company’s Minimum Value of Listed Securities, as defined by Nasdaq (“MVLS”), has been below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Minimum Market Value Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock, and its com

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-24-141847

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.